At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Vismodegib for Skin Basal Cell Carcinoma. Completed, enrolled 16 participants across 1 site.
Detailed Summary
This phase 1-2 trial studies how well pembrolizumab with or without vismodegib works in treating patients with skin basal cell cancer that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, are checkpoint inhibitors that stimulate immune response. Vismodegib may stop the growth of tumor cells by blocking signals needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Basal Cell Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, National Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionNov 2017
Study CompletionAug 2018
TodayJul 2026
First PostedFeb 24, 2016
Enrollment StartFeb 1, 2016
Primary CompletionNov 30, 2017
Study CompletionAug 29, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.4 years ago
Interventions
Pembrolizumabbiological
Given IV
Vismodegibdrug
Given PO